SCOPUS 정보 검색 플랫폼

New England Journal of Medicine

Volumn 367, Issue 25, 2012, Pages 2440-2442

Aquaretic treatment in polycystic kidney disease

(2) Wüthrich, Rudolf P a Mei, Changlin b

a UNIVERSITY HOSPITAL ZURICH (Switzerland)

b SECOND MILITARY MEDICAL UNIVERSITY (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PLACEBO; TOLVAPTAN; VASOPRESSIN;

DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HEMATURIA; HUMAN; HYPERNATREMIA; HYPONATREMIA; KIDNEY INFECTION; KIDNEY PAIN; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; NOCTURIA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; THIRST;

EID: 84871319305 PISSN: 00284793 EISSN: 15334406 Source Type: Journal
DOI: 10.1056/NEJMe1211857 Document Type: Editorial

Times cited : (14)

References (7)

1
- 34047276812
- Autosomal dominant polycystic kidney disease
- DOI 10.1016/S0140-6736(07)60601-1, PII S0140673607606011
- Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-301. (Pubitemid 46552051)
- (2007) Lancet , vol.369 , Issue.9569 , pp. 1287-1301
- Torres, V.E.¹ Harris, P.C.² Pirson, Y.³

2
- 80053904548
- Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience
- Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011;6:2499-507.
- (2011) Clin J Am Soc Nephrol , vol.6 , pp. 2499-2507
- Higashihara, E.¹ Torres, V.E.² Chapman, A.B.³

3
- 84871303897
- Tolvaptan in patients with autosomal dominant polycystic kidney disease
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18.
- (2012) N Engl J Med , vol.367 , pp. 2407-2418
- Torres, V.E.¹ Chapman, A.B.² Devuyst, O.³

4
- 79960426743
- Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
- Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011;80:295-301.
- (2011) Kidney Int , vol.80 , pp. 295-301
- Irazabal, M.V.¹ Torres, V.E.² Hogan, M.C.³

5
- 77956029702
- Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
- Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:820-9.
- (2010) N Engl J Med , vol.363 , pp. 820-829
- Serra, A.L.¹ Poster, D.² Kistler, A.D.³

6
- 24344470833
- Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease
- DOI 10.1111/j.1523-1755.2005.00395.x, PII 4494578
- Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206-16. (Pubitemid 43181378)
- (2005) Kidney International , vol.68 , Issue.1 , pp. 206-216
- Ruggenenti, P.¹ Remuzzi, A.² Ondei, P.³ Fasolini, G.⁴ Antiga, L.⁵ Ene-Iordache, B.⁶ Remuzzi, G.⁷ Epstein, F.H.⁸

7
- 69249235445
- A case for water in the treatment of polycystic kidney disease
- Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009;4:1140-50.
- (2009) Clin J Am Soc Nephrol , vol.4 , pp. 1140-1150
- Torres, V.E.¹ Bankir, L.² Grantham, J.J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.